The Science of Recovery-How Propoelix Supports the Body Against Dengue Fever

The Science of Recovery: How Propoelix™ Supports the Body Against Dengue Fever 

The Challenge: A Global Health Burden 

Dengue fever is an acute viral disease that has become a major international health problem. Over the last few decades, the number of cases reported to the World Health Organization has grown dramatically, with estimates of 50–100 million infections occurring annually worldwide. 

For patients, the disease is debilitating. It is characterized by high fever, severe headache, muscle pain, and in severe cases (Dengue Hemorrhagic Fever or DHF), a dangerous drop in platelet count known as thrombocytopenia. 

Despite its prevalence, there is currently no specific therapy available to treat the virus itself. Management has largely been "supportive"—meaning doctors treat the symptoms while the body fights the virus on its own. 

The Study: Putting the Hive to the Test 

In a rigorously conducted study at the Gatot Soebroto Central Army Hospital in Jakarta, researchers set out to determine if Propoelix™—HDI’s proprietary propolis extract—could improve outcomes for dengue patients. 

This was a double-blind, randomized, placebo-controlled trial. This is considered the "gold standard" of scientific research because neither the patients nor the doctors knew who was receiving the propolis and who was receiving the placebo, ensuring the results were unbiased. 

The Protocol: 

Finding #1: Significantly Faster Platelet Recovery 

This data confirms that Propoelix™ helps the body restore safe platelet levels significantly faster than standard care alone. 

Finding #2: Reducing Systemic Inflammation 

The severity of dengue is often linked to the body’s inflammatory response, specifically a marker called Tumor Necrosis Factor-alpha (TNF-$\alpha$)17. High levels of TNF-$\alpha$ are associated with more severe disease progression18. 

The clinical trial revealed that Propoelix™ acts as a potent anti-inflammatory: 

The Result: Going Home Sooner 

For patients and their families, the most important metric is how quickly they can leave the hospital and return to normal life. 

Because Propoelix™ accelerated platelet recovery and reduced inflammation, patients were medically fit for discharge earlier. The study showed that the Propoelix™ group had a significantly shorter length of hospitalization (average 4.69 days) compared to the placebo group (average 5.46 days).  

"Propoelix™ appears to hasten the improvement in platelet counts and TNF-$\alpha$ levels and shortens the duration of hospitalization in patients with DHF." — Infection and Drug Resistance Journal, 2014 

Why It Works: The Science of CAPE 

Propolis has been used since 300 BC by Greeks and Egyptians for its healing properties. However, raw propolis contains resins and waxes that are hard for the body to digest. 

Propoelix™ is unique because it uses a proprietary extraction process to remove these inert resins, leaving behind a water-soluble extract rich in active compounds. The key component is CAPE (Caffeic Acid Phenethyl Ester), a polyphenol proven to inhibit the production of inflammatory cytokines. 

Conclusion 

While prevention (avoiding mosquito bites) is always the first line of defense, this study confirms that Propoelix™ is a safe and effective adjunctive therapy for Dengue Hemorrhagic Fever. It was well-tolerated by all patients in the study, with no adverse effects on kidney or liver function. 

By combining ancient natural wisdom with modern clinical validation, Propoelix™ offers a powerful shield for your immune system when it needs it most. 

At a Glance: Clinical Trial Summary